Changing Pharmacy Reimbursements with CVS, FSS/IFF Reporting Alert, & the Latest in Sustain Act 340B
Table of contents
Changing Pharmacy Reimbursements with CVS
CVS Health has announced its plan to revamp its pricing strategy for prescription drug medication. This move aims to simplify the complex pricing model that has long been a pain point for patients, pharmacists, and payers alike.
As for their vision for change, here is what we know so far:
Transparency: CVS plans to provide greater transparency by offering “client pricing reflecting the true net cost of prescription drugs, with visibility into administrative fees.”
Integration of Care: CVS intends to roll out CVS Healthspire which will focus on delivering “connected patient care, pharmacy benefits, and innovative provider support solutions in communities across the country.”
This new change could have potential benefits to the current healthcare system. By focusing on delivering care with reducing costs, it would help improve health outcomes and the patient experience, especially for those with chronic conditions. Other players in the pharmaceutical ecosystem—such as pharmaceutical manufacturers, PBMs, and insurers—will closely watch CVS’s experiment. If it succeeds, we may see similar shifts elsewhere.
FSS/IFF Reporting Alert
VA FSS has closed the old FSS/GSA “VA Sales Portal.” In its place, manufacturers must transition their FSS sales reporting and IFF remittance duties to the Federal Acquisition (FAS) Sales Reporting Portal.
The new system goes live April 1, 2024. We recommend all pharma manufacturers attempt to sign into the new portal before the due date of the next reporting cycle to identify any sign-on problems. If you have trouble, you may contact the GSA Monday through Friday, 8:30 am to 5:30 pm EDT at (877) 495-4849 or vendor.suport@gsa.gov. For questions specifically related to the FAS Sales Reporting Portal, you may write to FSSRP@gsa.gov.
Latest in 340B Drug Discount Program: Draft Reform Bill "Sustain Act 340B"
Bipartisan senators issued an initial discussion draft bill and a request for information (RFI) to help curb the existing Sustain Act 340B abuse that has been long-standing in the industry, leading many pharma manufacturers to institute their own guidelines surrounding which entities they opt to provide discounted prices to. The 340B Program does not allow manufacturers to “discriminate” who they can and cannot provide 340B ceiling prices to; however, with the growing number of contract pharmacies and lack of appropriate transparency in place, manufacturers have felt the need to halt what they believe are out of control practices by covered entities.
The draft bill contains a few key provisions that help curtail the impropriety from both manufacturers and covered entities/HRSA:
- Prohibits manufacturers from placing restrictions on 340B drugs provided to covered entities that contract with contract pharmacies
- Requires hospitals to register their contract pharmacies with Health & Human Services (HHS) annually
- Requires hospitals to be more transparent in their processes and provide information required by manufacturers including the number of patients provided drugs at the 340B price
- Recommends charging of user fees to oversee the program, which would be no greater than % of the savings the covered entity receives under the 340B program
- Recommends establishing a clearing house for rebate claim scrubbing to prevent duplicate discounting, an area many manufacturers have struggled with for years
Additionally, the reform bill also proposes to provide clarity to the term “patient” to obtain alignment on what constitutes an “eligible” patient. The clarification requirement stems from the Genesis court hearing where the term “patient” was at the crux of the case.
Lastly, the bill also contains a provision to prohibit discriminatory practices towards covered entities and contract pharmacies from PBMs and GPOs.
Sources
The Washington Post, “CVS Pharmacy plans to overhaul how drugs are priced” (Dec. 2023).
CVS Health, “CVS Health highlights path to accelerating long-term growth through building a world of health around every consumer” (Dec. 2023).
Advis, “Senate Releases Draft 340B Bill - Requests Stakeholder Comments” (Feb. 2024).
Aimed Alliance, “Senators Seek Input on Draft 340B Reform Bill” (Feb. 2024).
Endpoints News, “Draft 340B reforms include user fees, clarity around contract pharmacies” (Feb. 2024).
About IntegriChain
IntegriChain delivers biopharma’s only comprehensive data-driven commercialization platform from strategy to operational execution, connecting the commercial, financial, and operational dimensions of drug access and profitability. Our ICyte® Platform integrates technology, data, consulting, and managed services to unify critical workflows, replacing manual processes with integrated analytics and precision controls.
Biopharma relies on IntegriChain to optimize patient access and net revenue performance, reduce leakage, and strengthen compliance, ensuring every life-changing therapy reaches patients with speed, affordability, and sustainability. Backed by Nordic Capital, a leading sector-specialized private equity investor with a broad portfolio in healthcare and technology.
IntegriChain is headquartered in Philadelphia, PA, with a location in Pune, India.